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Ancrod improves survival in murine systemic tupus erythematosus.
The effect of ancrod, a defibrinating agent, on murine lupus glomeru-
lonephritis in the male BXSB mouse was studied to determine the
relationship between macrophage procoagulant activity (PCA), fibrin
deposition and glomerulonephritis. Marked renal disease and fibrin
deposition were noted by three months of age in control mice, whereas
little or no disease was seen in ancrod treated mice until five months of
age. Similar high titers of anti-DNA antibodies and renal deposition of
IgG were seen in both groups of mice. PCA rose with age in both ancrod
treated and untreated mice, although it was significantly higher in
control animals than in the ancrod treated group. Furthermore, ancrod
therapy resulted in a decrease in plasma PCA inducing activity (PIF)
and a decrease in the effectiveness of PIF to induce PCA in peritoneal
macrophages in vitro. No mortality was observed in the 20 ancrod
treated mice, whereas 10 of 20 control animals died. We conclude that
defibrination with ancrod delays the development of renal fibrin depo-
sition and glomerulonephritis and improves survival in BXSB mice.
This was associated with a decrease in plasma PCA inducing activity
and with an inhibitory effect on PCA induction. These results suggest
that PCA contributes to injury in murine lupus glomerulonephritis by
promoting fibrin deposition.
A number of investigators have shown that injury in glomer-
ulonephritis (GN) is dependent upon activation of the coagula-
tion system. Defibrination reduced the incidence of glomerular
microthrombi [1], decreased fibrinogen deposition in the gb-
meruli with a reduction in crescent formation [2], and protected
against experimental nephrotoxic serum nephritis [3]. Pollak et
a! found that treatment with ancrod improved renal function
and reduced thrombi in patients with lupus GN [4]. Our
previous studies have shown that induction of monocyte/mac-
rophage (MO/MA) procoagulant activity (PCA) occurs in pa-
tients with active lupus nephritis, and also in the male BXSB
mouse as GN develops with age [5, 6]. Studies by Holdsworth
and Wiggins et al have also implicated PCA as being important
in the induction of injury in other experimental models of GN
[7—9].
The synthesis and secretion of PCA by MO/MA is now
known to be an integral component of the host's immune
response [10, 11]. PCA can be induced by a number of immu-
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nostimulatory molecules in collaboration with T lymphocytes,
and this process is tightly controlled by both helper and
suppressor cells as well as soluble mediators [12, 13]. The exact
means by which PCA leads to the development of injury in ON
is unknown. Theoretically, the molecule could be relevant by
directly promoting coagulation with formation of fibrin, or,
PCA might be chemotactic resulting in the recruitment of
inflammatory cells [14].
Ancrod is a proteolytic enzyme derived from the venom of
the Malayan Pit viper, Agkistrodo Rhodostoma, which causes
hypofibrinogenemia, hypoplasminogenemia, and an elevation in
fibrin degradation products [15, 16]. This molecule cleaves
fibrinopeptide A from fibrinogen without cleavage of fibrino-
peptide B, thereby preventing normal polymerization of fibrin.
In addition, ancrod activates the fibrinolytic system [16, 17].
These present studies were performed to assess the effect of
ancrod on the BXSB male mouse, which predictably develops
an age-related lupus-like ON [18], and specifically to determine
the relationship between PCA induction and fibrin deposition in
this model of GN.
Methods
Mice
BXSB male mice, four weeks of age, were obtained from
Jackson Laboratories, Bar Harbour, Maine, USA, and were
housed in the Department of Laboratory and Animal Services
at the University of Toronto. Blood urea nitrogen (BUN) was
determined using Azostix (Miles Laboratories, Rexdale, On-
tario, Canada).
Treatment protocols
Ancrod (Arvin) was obtained from Connaught Laboratories
Limited, Willowdale, Ontario, Canada. Ancrod was provided in
isotonic saline and 0.0025 M phosphate and 0.005% wt/vol
chlorbutol. Ancrod was diluted in RPMI-1640 (Flow Laborato-
ries, Mississauga, Ontario, Canada), and each mouse received
100 il of medium containing five units of ancrod by subcutane-
ous injection every Monday, Wednesday and Friday starting at
five weeks of age. This dosage had previously been determined
to reduce circulating fibrinogen to less than 30% of normal
values. As shown below, fibrinogen levels were subsequently
followed in all animals. At each time point, at least seven mice
from both ancrod treated and control groups were sacrificed
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and sera, kidney tissue and splenic mononuclear cells assessed.
Of necessity, mice sacrificed were those surviving up to that
point in time. Independently, survival was determined in two
cohorts (N = 20 in each group) of mice.
Fibrinogen levels
Two hundred j.tl of blood was collected from the retroorbital
plexus into heparinized tubes containing 10 1.d of 0.5 M sodium
citrate, pH 5, just prior to ancrod administration. Blood was
centrifuged for five minutes at 8,800 x g; plasma was then
removed, 50 j.d were added to 50 d of a 1/30 dilution of 30
mglml protamine sulphate (Eli Lilly Canada Inc., Toronto,
Canada), and then combined with 450 z1 of 25 mri CaC12 pH
7.2. The reaction was started by adding 50 .d of thrombin, (1000
pJml; Parke Davis Ltd., Toronto, Canada), and fibrinogen was
measured by a change in optical density (Lancer Fibrinogen
Analyzer, Sherwood Medical Industries, Cooksville, Ontario,
Canada), as compared to a fibrinogen standard. Fibrinogen
levels were measured in each mouse twice weekly for the first
week and once weekly thereafter and were reported in g/liter.
This assay measures clottable protein. Fibrin degradation prod-
ucts (FDP) have been shown not to interfere with the assay and
are not detected by this assay.
Cell isolation
Spleen cells. Spleens were removed aseptically from BXSB
mice, and cells were resuspended in RPMI 1640 medium (Flow
Laboratories, Mississauga, Ontario, Canada) as previously
described. Mononuclear cells were isolated by centrifugation
over Ficoll-Hypaque (density 1.034; Pharmacia, Montreal,
P.Q., Canada) at 1400 x g at 22°C for 12 minutes [6]. The cells
at the interface were removed and adjusted to 1 x 106 splenic
mononuclear cells per ml. The viability of these cells was
greater than 95% as demonstrated by trypan blue exclusion.
Since our previous studies have identified MO/MA as the
source of PCA within peripheral blood mononuclear cells!
spleen cells, assays for PCA were done on this total population
without further separation [6]. Studies of splenic cell popula-
tions showed no differences in the ratio of macrophages to
lymphocytes in the different treatment groups or time points.
The percentage of macrophages was quantified by nonspecific
esterase uptake, and was consistently 10 to 12% of total
mononuclear cells as previously described [6].
Peritoneal macrophages. Peritoneal macrophages were iso-
lated from four- to six-week old BXSB male mice three days
after intraperitoneal thioglycollate injection as previously de-
scribed [6]. Approximately l0 macrophages were isolated from
each animal.
Procoagulant activity
Samples of frozen-thawed and sonicated cells (total content
PCA) were assayed for the capacity to shorten recalcification
time of citrated normal pooled human plasma in a one-stage
clotting assay, as described previously [6]. Purified splenic
mononuclear cells at 1 x l06/ml in 12 x 75 mm polypropylene
tubes (Falcon Plastics, Oxnard, California, USA) were sub-
jected to three cycles of freeze-thaw and sonication. An aliquot
of the cellular homogenate (0.1 ml) was added to 0.1 ml of
citrated normal human platelet poor plasma (Helena Laborato-
ries, Beaumont, Texas, USA) at 37°C and 0.1 ml of 25 mrvi
CaCl2 was added to start the reaction. The time in seconds for
the appearance of a fibrin gel was recorded. To establish units,
a rabbit brain thromboplastin standard (Dade Division, Ameri-
can Hospital Supply, Miami, Florida, USA) at 36 mg dry mass
per ml was assigned a value of 100,000 mU. Log dilutions of this
standard were used to derive a standard curve as previously
described. Similarly, log dilutions of macrophages expressing
PCA gave a linear curve parallel to the thromboplastin standard
when plotted on a log-log scale. Media with or without 10% fetal
calf serum and buffers were all without activity [6].
Plasma procoagulant activity inducing factor
At the time of sacrifice, blood was collected from the axillary
artery of control and ancrod treated mice into heparinized
tubes. To assess procoagulant inducing factor (PIF), 20 d of
plasma from control or ancrod treated mice were added to 1 x
106 peritoneal macrophages from six-week-old male BXSB
mice which were supplemented with 6 X 106 splenic cells
suspended in 1 ml of RPMI 1640 (Flow Laboratories, Missis-
sauga, Ontario, Canada). The suspension was incubated over-
night, the medium was removed and the cells resuspended in 1
ml of RPMI 1640. Cells (1 x 106) were subjected to three cycles
of freeze-thawing and sonication and assayed for total content
PCA as above.
Effect of ancrod on procoagulant activity inducing factor
(PIF)
In order to determine whether ancrod was able directly to
inhibit the ability of PIF to induce PCA, peritoneal macro-
phages were stimulated with 20 d of positive plasma from
six-month-old BXSB mice, or 10 of lipopolysaccharide
(LPS; E. coli 0111 :B4) or 20 g of human IgG aggregated by
heating to 63°C for 20 minutes in the presence or absence of
increasing concentrations of ancrod up to 5 U/ml.
Endotoxin contamination
All media and buffers were assayed for endotoxin contami-
nation by a standard limulus assay (E. Toxate; Sigma Chemical
Co., St. Louis, Missouri, USA) and contained less than 0.1
nglml of endotoxin, the lower limits of the assay.
Assay for anti-DNA antibodies
Single stranded DNA (ssDNA) was prepared by placing calf
thymus DNA type I (Sigma Chemical Co.; diluted to 1 mglml in
distilled water), in a boiling water bath for 15 minutes followed
by rapid cooling in an ice bath for 15 minutes. One hundred
microliters of the denatured DNA diluted to 2.5 g/ml in 0.9%
saline, was placed into the wells of a 96-well polystyrene plate
(NUNC, Gibco Scientific, Mississauga, Ontario, Canada)
which in turn was incubated overnight at 4°C. After washing in
distilled water containing 0.05% Tween 20, the plates were
blocked with 3% bovine serum albumin, washed and then
air-dried before use in the assay.
Sera in serial twofold dilutions were added to the coated
DNA plates along with appropriate positive (sera from NZB
and MRL!1 mice) and negative (sera from DBAI2 and CBA/J)
controls. After a 60 minute incubation at room temperature, the
plates were washed as above, following which 100 p1 of diluted
peroxidase-conjugated, affinity purified, goat anti-mouse 1gM or
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Table 1. Effect of ancrod on plasma fibrinogen, blood urea nitrogen and survival
Plasma fibrinogena Blood urea nitrogenL Survival
Age of mice
months
giliter mg/100 ml % of total
Control Ancrod Control Ancrod Control Ancrod
1.25 2.46 0.8 1.95 0.75 — — 100 100
2.00 1.95 0.65 0.45 0.l8C 10 2 10 2 80 100
3.00 1.25 0.3 0.47 0.17° 15 1.9 15.1 1.5 70 100
4.00 1.4 0.2 0.49 0.2° 30 5 15 4° 60 100
5.00 1.35 0.11 0.35 0.05° 40.5 5 23 6° 55 100
6.00 1.45 0.22 0.67 0.3° 49.5 5.5 10 1° 50 100
Data are expressed as the mean standard error of the mean,
a 4 animals/group/time point (normal fibrinogen = 1 to 3 g/liter)
7 mice per group
P < 0.01
— not done
IgG antibody (Jackson Immunoresearch, Avondale, Pennsylva-
nia, USA) was added to each well. The plates were incubated at
room temperature for 60 minutes. After washing, 100 d of
0.015% hydrogen peroxide substrate containing 0.2% o-phenyl-
ene diamine was added and incubated for 30 minutes at RT. The
optical density at 450 nm of each well was determined using an
MR-600 plate reader (Dynatech Industries, McLean, Virginia,
USA). The results were expressed as optical density units
where absorbance values 2 standard deviations above the mean
of normal controls (0.200 O.D.) were deemed to be positive.
The assay for anti-double stranded DNA (anti-dsDNA) was
performed identically to the anti-ssDNA antibody assay omit-
ting the denaturation step.
Renal pathology
Whole kidneys were removed from sacrificed animals. Spec-
imens for histologic study were embedded in paraffin. Thereaf-
ter, 4 micron sections were stained with hematoxylin and eosin,
(H & E) and were reviewed by a pathologist (JS) in a double
blind fashion. Biopsies were assessed by a scoring system
similar to that used by Balow and colleagues in the assessment
of activity in human lupus nephritis [19], and points were
assigned as follows: glomerular cellular proliferation-3, leuko-
cyte exudation-3, karryorrhexis or fibrinoid necrosis-6, cellular
crescents-6, hyaline deposits-3, interstitial inflammation-3.
Immunofluorescence
Portions of kidneys were embedded in Tissue-Tech (Miles
Laboratories, Napleville, Illinois, USA) and snap-frozen in
liquid nitrogen. Thereafter, the samples were kept at —70°C
prior to further assessment. Three micron sections were cut and
to determine fibrinogen deposition were stained initially with
rabbit anti-mouse fibrinogen (Dr. E. Plow, Scripps Clinic and
Research Foundation, La Jolla, California, USA), and thereaf-
ter with fluorescein isothiocyanate conjugated goat anti-rabbit
IgG (Cappel Laboratories, Cochranville, Pennsylvania, USA).
The goat anti-rabbit IgG was absorbed with normal mouse
serum prior to use. To determine IgG deposition, sections were
stained with fluorescein isothiocyanate labelled goat anti-mouse
IgG (Cappel Laboratories). The sections were subsequently
assessed by JS in a double blind manner.
Statistical analysis
Data from both ancrod treated and control mice were com-
pared by means of the Wilcoxon Rank Sum Test, giving a
comparison of two independent variables at various time
points.
Results
Fibrinogen levels
These data are shown in Table 1. As can be seen, up to five
months of age, plasma fibrinogen was maintained at less than
30% of control values. However, at six months of age, despite
continued therapy, plasma fibrinogen rose to 52% of control
values (0.77 g/liter vs. 1.47 mg/liter).
Blood urea nitrogen
Table I compares BUN in ancrod treated and control mice.
The values are significantly higher (P < 0.01) in the controls at
four, five and six months.
Anti-DNA antibodies
DNA binding assessed by all parameters (IgG, 1gM, single
and double stranded DNA) varied from 1: 100 to 1:3200. There
were no differences in any parameter at any time point between
control and ancrod treated animals (data not shown).
Mortality
A striking difference was observed in mortality between
those animals treated with ancrod and control mice. Over a six
month perio , none of 20 animals in the ancrod treated group
died, whereas 10 out of 20 control animals (50%) died. These
data are shown in Table 1.
Procoagulant activity
Spontaneous PCA was assessed in both control and ancrod
treated mice as shown in Figure 1. An increase in PCA was
observed in splenic cells from two-month-old BXSB mice, rose
markedly by three months and persisted for the length of the
study. In contrast, a lesser rise in PCA was observed in ancrod
treated mice at three months and a significant difference in PCA
values between control and treated mice was seen from two
months of age on.
Procoagulant activity inducing factor (PIF)
PIF was compared in ancrod treated and control mice. The
latter group had PIF values significantly higher than ancrod
treated mice (P < 0.01) from two months of age on. However,
a modest increase in PIF also occurred in the treated animals
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Fig. 2. A comparison of plasma procoagulant-inducing factor in con-
trol () and ancrod treated () mice. Values represent the mean
standard error of the mean of 5 assays done in duplicate. The values at
2 to 6 months of age were significantly different between the two groups
(P < 0.01).
Age of mice, months
Fig. 1. Spontaneous procoagulant activity in control () and ancrod
treated () BXSB mice. Values represent the means 1 standard error
of the mean of mice/group. The differences between ancrod treated and
control animals were significant (P < 0.01) at 2 and 3 months of age, and
significant (P < 0.5) at 4, 5 and 6 months of age.
starting at three months of age (Fig. 2). No PIF was found in
plasma from four-week-old BXSB mice or two- and four-month
old A/J or Balb/cJ mice (data not shown).
Effect of ancrod on PIF
Ancrod had no effect on the ability of lipopolysaccharide
(LPS) to induce procoagulant activity in peritoneal macro-
phages, whereas it was markedly inhibitory to the stimulatory
effects of aggregated mouse IgG and PIF. Forty-two percent
inhibition of PIF induced PCA was observed at a concentration
of 1.25 U/mI ancrod, and 68% inhibition at 5 U/mI. One hundred
percent inhibition of aggregated IgG induced PCA was ob-
served at all concentrations of ancrod tested (Table 2).
Histology
The activity index was assessed for all mice. Mean activity
scores are presented in Figure 3 and show that control mice had
significantly more active glomerulonephritis (Fig. 4A and B) at
three, four and five months of age (P < 0.01). At five and six
months of age severe histologic disease was seen in both treated
and untreated mice, although at five months of age, five of
seven ancrod treated mice had normal kidneys (Activity index
= 0).
Immunofluorescence
Immunofluorescence was graded from negative to 3+. Con-
trol animals had increasing amounts of glomerular fibrin from
two months of age, which was significantly greater than that
Table 2. Effect of ancrod on procoagulant activity inducing factor
Stimulus
Aggregated
Ancrod
U/mi
Control LPS IgG Plasma
PCA mU/lOó peritoneal macrophages
— 174 54 1750 25 439 71 3296 243
0.3125 — 1489 154 142 16 3845 327
0.625 — 1500 143 — —
1.25 — 1309 193 136 ioa 1900 182a
2.5 — 1472±188 — —
5.0 194 39 1533± 169 146 ioa 1064 ll8a
LPS (E. coil 0111 :B4) was added at a final concentration of 10 g/ml.
Ancrod (Arvin) concentration is expressed as units/mi.
Aggregated IgG (Agg IgG) was mouse IgG at a final concentration of
0.9 mg/mI. Positive plasma was isolated from 5-month-old BXSB mice
and 20 /Ll was added to each culture. PCA is total content procoagulant
activity in mU/b6 peritoneal macrophages.
a P < 0.01 as compared to PCA without ancrod
present in treated mice at all time points (P < 0.01). At four
months of age, when disease was well established, glomeruli
from control mice were strongly positive (2 to 3+) for fibrinogen
(Fig. 4C), whereas ancrod treated mice were negative or had
only trace amounts (Fig. 4D).
Both control and ancrod treated mice had marked and
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Fig. 3. Renalactivity index in BXSB mice. Symbols are: () control;
(U) ancrod treated mice. Values are derived as described in Methods
and are the mean I standard error of the mean. There was no activity
in either group of mice at 2 months of age and in ancrod treated mice at
3 months of age. There was a significant difference between the 2 groups
of mice at 3, 4 and 5 months of age.
equivalent deposition of IgG in renal glomeruli from three
months of age on. In three-month-old mice, deposition was
primarily within the mesangium, while older mice generally had
prominent capillary loop deposition as well.
Discussion
Fibrin deposition is a prominent feature of many forms of
GN, although the mechanism is uncertain [2—4]. We have
recently demonstrated that monocytes (human) and splenic
macrophages (mouse) contain large amounts of PCA in both
patients and mice with active lupus GN [5, 6]. Wiggins, Glat-
feller and Brukman [7] and Holdsworth and Tipping [8] have
demonstrated induction of PCA in macrophages isolated from
glomeruli of animals with antiglomerular basement membrane
antibody mediated glomerulonephritis. Rickles and colleagues,
using a monoclonal antibody against macrophage activation
antigen, have shown surface expression of PCA in patients with
active GN [201. These data suggest participation of macrophage
PCA in glomerular injury. Induction of macrophage PCA pre-
ceded fibrin deposition and may be responsible for its presence
in active disease [9]. This does not prove that fibrin is formed as
a consequence of PCA induction, but it is highly suggestive.
Our previous data and that of others have shown a 50%
mortality at five months in the BXSB male mouse [6, 21]. These
present studies demonstrate that ancrod, given intermittently to
BXSB mice in doses sufficient to reduce fibrinogen, signifi-
cantly improved mouse survival. While we were unable to
perform detailed studies on animals that died, we attributed
their death, as emphasized by others, to renal failure secondary
to GN [21]. This was associated with a decrease in glomerular
fibrin deposition, improved renal function and a delay in the
appearance of active GN. However, circulating anti-DNA
antibody levels and renal IgG deposition were unaffected,
indicating no effect of ancrod on autoantibody production or
renal immune complex (IC) deposition. The documented delay
in renal disease is even more remarkable if one considers that
control animals studied were survivors and thus had less severe
disease than control mice that died of disease and could not be
studied. The onset of more severe glomerular disease and fibrin
accumulation in five- to six-month ancrod-treated mice, asso-
ciated with an increase in plasma fibrinogen levels, may be
related to resistance to ancrod as has been described. The
mechanism for this resistance is unknown but could be related
to the development of antibodies to ancrod [22].
These data support the concept that fibrin deposition is
crucial to the development of serious glomerular injury in this
mouse strain. Fibrin likely contributes to injury by reducing
blood flow through glomerular capillaries, and by recruitment of
inflammatory cells through the creation of a meshlike network
[23].
The amelioration of UN seen in association with fibrin
depletion was accompanied by an unexpected sustained reduc-
tion in PCA and PIF, although the major effect was seen at
months two and three. The fact that both renal function and
survival were so profoundly affected despite no effect on
formation and deposition of IC emphasizes the requirement for
subsequent activation of mediator systems in order for inflam-
mation and disease to occur. The mechanism by which ancrod
reduced PCA induction is uncertain. Our previous work has
demonstrated that a circulating plasma factor (PIF), which
develops with age, is responsible for inducing PCA in BXSB
mice [6]. Studies in our laboratory have shown no inhibitory
effect of ancrod on the PCA assay itself. However, ancrod
markedly inhibited the ability of aggregated IgG and plasma
from five-month-old BXSB mice to induce PCA in vitro in
macrophages from six-week-old mice, whereas it had no inhib-
itory effect on LPS induction of PCA (Table 2). This data
suggests that ancrod interferes with the interaction of PIF and
mononuclear cells resulting in reduced levels of PCA. The
nature of PIF in this model is unknown; however, recent studies
in our laboratory have shown it to have a molecular weight of
400,000 to 900,000 daltons (manuscript in preparation). Studies
in human lupus using endothelial cells have suggested the
stimulatory factor to be IC [24]. The similarity of inhibition by
ancrod of plasma and aggregated IgG PCA induction is consis-
tent with this hypothesis. Although ancrod did inhibit PCA
induction, the beneficial effect of the drug is probably related to
the creation of abnormal fibrinogen preventing the formation of
fibrin.
These data are in agreement with those of Tipping and
Holdsworth, who showed that accumulation of glomerular
macrophages preceded that of fibrin, and that the latter paral-
leled the development of glomerular crescents and impairment
of renal function in an experimental model of antiglomerular
basement membrane antibody-induced disease in the rabbit [9].
They have also shown benefit of both fibrinolysis and defibrina-
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Fig. 4. Renal histology and immunofluorescence in BXSB mice. (A) Severe proliferative glomerulonephritis in control mice at 4 months. (H & E
x 200). (B) Normal glomerulus from ancrod treated mouse at 4 months of age. (H & E X 200). Immunofluorescence using a rabbit anti-mouse
fibrinogen demonstrating: (C) fibrin deposition in glomeruli of control animal at 4 months of age, whereas (D) glomeruli from ancrod treated mice
had only trace amounts of fibrin (x 20).
tion in this disease but did not assess PCA [25]. These studies
are also consistent with data of Cohen et al showing that
anticoagulants interfere with delayed hypersensitivity reac-
tions, not by interfering with the process of sensitization, but by
acting at a critical step in the formation of the inflammatory
infiltrate [26].
Unlike certain other anticoagulants, the effect of ancrod is
specific, in that it has no effect on coagulation, other than
directly converting fibrinogen to a soluble form of fibrin which
is rapidly removed by the reticuloendothelial system [27].
Pollak and colleagues have shown that the resulting production
of fibrin does not alter IC clearance by the reticuloendothelial
system, and would not be expected to affect the course of GN
by that mechanism [281. Nevertheless, it has also been noted
that FDP which accumulate in some patients on ancrod therapy
suppress lymphocyte immune responsiveness in vitro [29].
Since autoantibody production and renal IC deposition were
unaffected by ancrod, depressed lymphocyte responsiveness
was probably not responsible for the amelioration of lupus GN
seen in this study.
The profound effect of ancrod on mortality in this study,
along with the reports by Pollak and Holdsworth, suggest that
this agent may be clinically useful in the therapy of lupus
nephritis, although it does not appear to alter the formation or
deposition of IC [4, 26]. Future experiments will be directed
towards further definition of the role of PCA in GN and
autoimmune disease and characterization of PIF.
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